小児髄芽細胞腫に対するプロトン対光子放射線療法: 体系的なレビューとメタ解析

Lucca B Palavani¹, Pedro G L B Borges², Gabriel Semione³

¹Max Planck University Center, Indaiatuba, São Paulo, Brazil.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery

|August 23, 2025

まとめ

陽子束放射線療法 (PBRT) と光子放射線療法 (XRT) は,小児髄芽細胞腫の生存率に類似しています. PBRTはXRTと比較して軽度の合併症のリスクを大幅に軽減します.

科学分野:

腫瘍学
放射線腫瘍学
小児神経腫瘍学

背景:

放射線治療の進歩は中枢神経系がんの治療に変革をもたらしました
小児の髄芽細胞腫は精密で効果的な治療法が必要です

研究の目的:

陽子束放射線療法 (PBRT) と光子放射線療法 (XRT) の有効性と安全性を比較する.
PBRTとXRTの生存率と合併症プロフィールの違いを分析する.

主な方法:

1319件のスクリーニングされた研究の体系的レビューと比較メタ解析.
小児患者889人 (PBRT509人,XRT380人) を含む9つのコホートを含む.
ランダム効果モデルを用いた5年生存率と合併症の分析

主要な成果:

PBRTとXRTの5年生存期に統計的に有意な差はない (OR0. 86).
大事な合併症の発生率は,PBRTとXRT群の間で比較可能であった (OR0. 82).
軽微な合併症はPBRT群では著しく少ない (OR 0. 11,p < 0. 01).

結論:

陽子束放射線療法 (PBRT) は,小児髄膜芽細胞腫における光子放射線療法 (XRT) に比べて軽度の合併症の発生率が低い.
PBRTはXRTと同等の安全性と有効性を提供し,周囲の組織への放射線量が減少する可能性があります.

キーワード:

骨髄芽細胞腫メタ解析光子放射線療法プロトン放射線療法治療の結果

さらに関連する動画

07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.9K

10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

9.6K

関連する概念動画

02:56

Treatment Resistant Cancers

3.4K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

3.4K

02:49

Cancer Therapies

7.9K

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

7.9K

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...